Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
Neurofilament light chain (NfL) is a significant biomarker that indicates the level of neuronal axon degeneration occurring in the subcortex of the brain. Elevated levels of NfL can be detected in both plasma and cerebrospinal fluid (CSF) and are associated with various neurodegenerative disorders, including Alzheimer's disease, multiple sclerosis, frontotemporal dementia, and amyotrophic lateral sclerosis. The presence of NfL in the blood is particularly noteworthy, as it is typically not found in significant amounts under normal conditions. This biomarker is released into the CSF during neuronal injury and subsequently enters the bloodstream. The plasma-based assay for NfL is particularly valuable in clinical settings, as it aids in differentiating whether a decline in cognitive function is attributable to a neurodegenerative disorder. Traditional testing methods primarily utilize CSF samples; however, advancements have led to the development of blood tests that can detect NfL levels. These blood-based tests not only streamline the diagnostic process by potentially reducing the need for more invasive procedures but also serve as effective tools for monitoring disease progression and evaluating treatment responses in patients with neurodegenerative conditions.
© Copyright 2026 Coding Ahead. All rights reserved.
The neurofilament light chain (NfL) test is indicated for the assessment of various neurodegenerative disorders. The following conditions are explicitly associated with the use of this biomarker:
The procedure for testing neurofilament light chain (NfL) involves several key steps to ensure accurate measurement of this biomarker. The following procedural steps are outlined:
Post-procedure care for patients undergoing NfL testing is generally minimal, especially for blood plasma collection. Patients may experience slight discomfort or bruising at the venipuncture site, which typically resolves quickly. In the case of CSF collection, patients may be advised to rest and hydrate adequately to minimize the risk of post-lumbar puncture headache. Follow-up appointments may be scheduled to discuss the results of the NfL test, and further diagnostic or therapeutic measures may be considered based on the findings. Continuous monitoring of NfL levels can be beneficial in assessing disease progression and response to treatment in patients diagnosed with neurodegenerative disorders.
| Short Descr | ASSAY NEURFLMNT LIGHT CHAIN | Medium Descr | ASSAY NEUROFILAMENT LIGHT CHAIN | Long Descr | Neurofilament light chain (NfL) | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | Not applicable/unspecified. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2025-01-01 | Added | Code Added. |
Get instant expert-level medical coding assistance.